Dear industry: Do not accept any more lectures on transparency

March 4, 2020 Comment

This is a preview of subscriber content

Subscribe now to continue reading.

A lot of people spend a lot of time lecturing the biopharmaceutical industry about a range of issues, including transparency - yet there is a clear double-standard. …

Subscribe now to continue reading.

Latest Video

Pfizer updates on promising step towards a Lyme disease vaccine candidate
March 24, 2026 - Latest News
Australian biotech surges in response to trial suggesting a new hope in the fight against pancreatic cancer
March 24, 2026 - Latest News
A new chapter for National Pharmacies as experienced executive steps into customer leadership
March 24, 2026 - Latest News
Australia moves closer to Europe as health and research ties deepen under landmark agreement
March 25, 2026 - Latest News
Small changes can still become foundations for the meaningful, but understand how decisions are made
March 25, 2026 - Latest News

Dear industry: Do not accept any more lectures on transparency

This is a preview of subscriber content

Latest Video

Most Read

Pfizer updates on promising step towards a Lyme disease vaccine candidate

Australian biotech surges in response to trial suggesting a new hope in the fight against pancreatic cancer

A new chapter for National Pharmacies as experienced executive steps into customer leadership

Australia moves closer to Europe as health and research ties deepen under landmark agreement

Small changes can still become foundations for the meaningful, but understand how decisions are made

New Stories

Liberty expands into Asia Pacific life sciences insurance with new tailored offering

Budget delivers progress, but hundreds of thousands still waiting for access

To what extent does the system even see itself as bound by external review?

PBAC agenda reflects increasing number of companies seeking revised recommendations

Community pharmacies set to expand patient care following Labor re-election in South Australia

Clarity advances US manufacturing strategy with major copper 64 supply agreement

As 'Horizon Europe' winds down, its successor program remains a work in progress

Sign In

Dear industry: Do not accept any more lectures on transparency

This is a preview of subscriber content

Latest Video

Most Read

Pfizer updates on promising step towards a Lyme disease vaccine candidate

Australian biotech surges in response to trial suggesting a new hope in the fight against pancreatic cancer

A new chapter for National Pharmacies as experienced executive steps into customer leadership

Australia moves closer to Europe as health and research ties deepen under landmark agreement

Small changes can still become foundations for the meaningful, but understand how decisions are made

Follow Us

New Stories

Liberty expands into Asia Pacific life sciences insurance with new tailored offering

Budget delivers progress, but hundreds of thousands still waiting for access

To what extent does the system even see itself as bound by external review?

PBAC agenda reflects increasing number of companies seeking revised recommendations

Community pharmacies set to expand patient care following Labor re-election in South Australia

Clarity advances US manufacturing strategy with major copper 64 supply agreement

As 'Horizon Europe' winds down, its successor program remains a work in progress